Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 06101 | Wellpoint Federal | MAC - Part A | IL |
| 06201 | Wellpoint Federal | MAC - Part A | MN |
| 06301 | Wellpoint Federal | MAC - Part A | WI |
| 06102 | Wellpoint Federal | MAC - Part B | IL |
| 06202 | Wellpoint Federal | MAC - Part B | MN |
| 06302 | Wellpoint Federal | MAC - Part B | WI |
| 13101 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13201 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13102 | Wellpoint Federal | A and B and HHH MAC | CT |
| 13202 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13282 | Wellpoint Federal | A and B and HHH MAC | NY |
| 13292 | Wellpoint Federal | A and B and HHH MAC | NY |
| 14411 | Wellpoint Federal | A and B and HHH MAC | RI |
| 14211 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14311 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14511 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14111 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14112 | Wellpoint Federal | A and B and HHH MAC | ME |
| 14212 | Wellpoint Federal | A and B and HHH MAC | MA |
| 14312 | Wellpoint Federal | A and B and HHH MAC | NH |
| 14512 | Wellpoint Federal | A and B and HHH MAC | VT |
| 14412 | Wellpoint Federal | A and B and HHH MAC | RI |
Billing and coding article A58116: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58116 (Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM)) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A58116: Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM) (Billing and Coding, effective 2026-09-10)
- Covered ICD-10-CM codes
- 373
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 3
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| E08.00 | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) |
| E08.01 | Diabetes mellitus due to underlying condition with hyperosmolarity with coma |
| E08.10 | Diabetes mellitus due to underlying condition with ketoacidosis without coma |
| E08.11 | Diabetes mellitus due to underlying condition with ketoacidosis with coma |
| E08.21 | Diabetes mellitus due to underlying condition with diabetic nephropathy |
| E08.22 | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease |
| E08.29 | Diabetes mellitus due to underlying condition with other diabetic kidney complication |
| E08.311 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema |
| E08.319 | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema |
| E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral |
| E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye |
| E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye |
| E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye |
| E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral |
Procedure codes: 0446T, 0447T, 0448T.
Coverage indications, limitations and medical necessity
Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.
History/Background and/or General Information
Covered Indications
I-CGMs are class III medical devices that require premarket approval by the FDA. In order to be considered reasonable and necessary, the FDA approved indication must include use as a therapeutic CGM. 1 The FDA recently approved expanding the indications of an implantable CGM product to replace fingerstick blood glucose measurements for diabetes treatment decisions.
Therapeutic I-CGMs are considered reasonable and necessary by Medicare when all of the following coverage criteria (1-4) are met:
• The beneficiary has diabetes mellitus (Refer to the ICD-10 code list in the LCD-related Policy Article for applicable diagnoses); and,
• The beneficiary's treating practitioner has concluded that the beneficiary (or beneficiary's caregiver) has sufficient training using the I-CGM prescribed as evidenced by providing a prescription; and,
• The I-CGM is prescribed in accordance with its FDA indication for use; and,
• The beneficiary for whom a I-CGM is being prescribed, to improve glycemic control, meets at least one of the criteria below:
• The beneficiary is insulin-treated; or,
• The beneficiary has a history of problematic hypoglycemia with documentation of at least one of the following:
• Recurrent (more than one) level 2 hypoglycemic events (glucose
• A history of one level 3 hypoglycemic event (glucose
CMG Continued Coverage
Every six (6) months following the initial prescription of the CGM, the treating practitioner conducts an in-person or Medicare approved telehealth visit with the beneficiary to document adherence to their CGM regimen and diabetes treatment plan.
Limitations
I-CGM devices will not be considered reasonable and necessary for short-term (72 hours to 1 week) diagnostic use.
Exception
For those beneficiaries who have previously met the coverage criteria for a non-implantable therapeutic continuous glucose monitor through the Medicare DME benefit and subsequently choose to switch to the implantable device, they may do so with a provider order. However, all other coverage criteria above must be fulfilled in order for Medicare payment.
Summary of evidence (opening)
Background
Diabetes mellitus is a chronic metabolic disease involving an underproduction or resistance to insulin, resulting in elevated blood glucose levels. The two most common types of diabetes are type 1 (T1DM) and type 2 (T2DM). 2 T1DM comprises approximately 5-10% of diabetes cases, and describes an etiology in which an autoimmune response damages the insulin-producing beta cells of the pancreas, resulting in insufficient insulin production. Conversely, T2DM is characterized by insulin resistance. 2,3 In T2DM, an individual’s insulin production fails to offset the deficit that is created by the resistance. 2 T2DM constitutes an estimated 90%-95% of diabetes cases. 3
Approximately 11.3% of Americans have diagnosed diabetes, and an additional 3.4% of Americans are estimated to have undiagnosed diabetes. The prevalence of diabetes is known to increase with age. In Medicare aged populations in the United States (≥ 65 years of age), 22.4% of the population has diagnosed diabetes, with an additional 4.7% estimated to have undiagnosed diabetes. 4 Economic evaluations have estimated that diabetes annually accounts for $237 billion in direct US medical expenditure, and an additional $90 billion in lost productivity. 5
Acute complications of diabetes include hypoglycemia, hyperglycemia, diabetic coma, and nonketotic hyperosmolar coma. Chronic hyperglycemia, resulting from poorly controlled diabetes, may result in serious and life-threatening damage, including dysfunction and failure of the eyes, kidneys, nervous system and cardiovascular system. The complications of diabetes mellitus are far less common and less severe in people who have well-controlled blood sugar levels. 2
The contractor cites 40 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2020-12-01
- Current revision effective
- 2026-04-01
- MCD version
- 21
Other related documents: A59659 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L38623 cover?
• The beneficiary's treating practitioner has concluded that the beneficiary (or beneficiary's caregiver) has sufficient training using the I-CGM prescribed as evidenced by providing a prescription; and, The full 342-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L38623 apply to?
Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; 6 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L38623?
The companion billing and coding article A58116 lists 373 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L38623?
A denial under LCD L38623 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58116's 373 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.